Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence

Chordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in c...

Full description

Bibliographic Details
Main Authors: Jeffrey I. Traylor, Mark N. Pernik, Aaron R. Plitt, Michael Lim, Tomas Garzon-Muvdi
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/10/2408
id doaj-18c8e8a143834662b47d27f707958f30
record_format Article
spelling doaj-18c8e8a143834662b47d27f707958f302021-06-01T00:12:27ZengMDPI AGCancers2072-66942021-05-01132408240810.3390/cancers13102408Immunotherapy for Chordoma and Chondrosarcoma: Current EvidenceJeffrey I. Traylor0Mark N. Pernik1Aaron R. Plitt2Michael Lim3Tomas Garzon-Muvdi4Department of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurosurgery, Stanford University Medical Center, Stanford, CA 94305, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USAChordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in chordoma and chondrosarcoma alike. In chordoma, brachyury has been identified as a prominent biomarker and potential molecular immunotherapy target as well as PD-1 inhibition. While studies on immunotherapy in chondrosarcoma are sparse, there is emerging evidence and ongoing clinical trials for PD-1 as well as IDH inhibitors. This review highlights potential biomarkers and targets for immunotherapy in chordoma and chondrosarcoma, as well as current clinical evidence and ongoing trials.https://www.mdpi.com/2072-6694/13/10/2408chordomachondrosarcomabrachyuryPD-1immunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Jeffrey I. Traylor
Mark N. Pernik
Aaron R. Plitt
Michael Lim
Tomas Garzon-Muvdi
spellingShingle Jeffrey I. Traylor
Mark N. Pernik
Aaron R. Plitt
Michael Lim
Tomas Garzon-Muvdi
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
Cancers
chordoma
chondrosarcoma
brachyury
PD-1
immunotherapy
author_facet Jeffrey I. Traylor
Mark N. Pernik
Aaron R. Plitt
Michael Lim
Tomas Garzon-Muvdi
author_sort Jeffrey I. Traylor
title Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
title_short Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
title_full Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
title_fullStr Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
title_full_unstemmed Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
title_sort immunotherapy for chordoma and chondrosarcoma: current evidence
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-05-01
description Chordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in chordoma and chondrosarcoma alike. In chordoma, brachyury has been identified as a prominent biomarker and potential molecular immunotherapy target as well as PD-1 inhibition. While studies on immunotherapy in chondrosarcoma are sparse, there is emerging evidence and ongoing clinical trials for PD-1 as well as IDH inhibitors. This review highlights potential biomarkers and targets for immunotherapy in chordoma and chondrosarcoma, as well as current clinical evidence and ongoing trials.
topic chordoma
chondrosarcoma
brachyury
PD-1
immunotherapy
url https://www.mdpi.com/2072-6694/13/10/2408
work_keys_str_mv AT jeffreyitraylor immunotherapyforchordomaandchondrosarcomacurrentevidence
AT marknpernik immunotherapyforchordomaandchondrosarcomacurrentevidence
AT aaronrplitt immunotherapyforchordomaandchondrosarcomacurrentevidence
AT michaellim immunotherapyforchordomaandchondrosarcomacurrentevidence
AT tomasgarzonmuvdi immunotherapyforchordomaandchondrosarcomacurrentevidence
_version_ 1721415470734639104